1. 1. Harsha H. C., Kandasamy K., Ranganathan P., Rani S., Ramabadran S., Gollapudi S. and et al.: A compendium of potential biomarkers of pancreatic cancer, PLoS. Med., 2009, 6(4) 18-24.
2. 2. Iodice S., Gandini S., Maisonneuve P., and Lowenfels A. B.: Tobacco and the risk of pancreatic cancer: a review and meta-analysis, Langenbeck's Arch. Surg., 2008, 393(4) 535-545.
3. 3. Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K. and, et al.: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors, Cancer Res., 1999, 59(20) 5209-5218.
4. 4. Ciardiello F., Caputo R., Damiano V., Troiani T., Vitagliano D., Carlomagno F. and et al.: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase, Clin. Cancer Res., 2003, 9(4) 1546-1556.
5. 5. Wedge S. R., Ogilvie D. J., Dukes M., Kendrew J., Curwen J. O., Hennequin L. F. and et al.: ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy, Cancer Res., 2000, 60(4) 970-975.